CASI Pharmaceuticals Inc. (NASDAQ: CASI) announced that China's National Medical Products Administration has approved a clinical trial application for a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE